In this webinar, we look at how nanobody discovery and screening platforms exploit high-throughput flow cytometry to increase the throughput of nanobody screening campaigns.
Nanobodies are small, single-domain antibody fragments that retain full antigen-binding capabilities and the properties of heavy-chain antibodies. While antibodies are set to be increasingly important as therapeutic options for cancer and other diseases, the discovery of fully functional antibodies that lack light chains in Camelidae (camels and llamas) has opened the door to an exciting new generation of therapeutic antibodies known as nanobodies.
Unlike conventional antibodies, the heavy-chain antibodies of Camelidae contain a single variable domain (VHH) and two constant domains (CH2 and CH3) only. Using these functional antibodies as a base, nanobodies have been created and represent the next generation in antibody-derived biologics.
Join Dr. Pieter Kennis to learn about:
Attend the live webinar on Tuesday, November 7, at:
Certificate of Attendance
All webinar participants can request a certificate of attendance, and a learning outcomes summary document for continuing education purposes.
Find out more on this topic by registering to watch the full webinar>>
SelectScience runs 3-4 webinars a month across various scientific topics, discover more of our upcoming webinars>>